The effect of memantine on cognitive impairment in schizophrenia

Evaluating the Efficacy of Memantine as an adjuvant therapy for cognitive impairment in 18 to 45 year-old patients with schizophrenia- Interventional - Randomized controlled clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250430065539N2

Enrollment

Registered

2025-06-06

Start date

2025-06-22

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Intervention group: Intervention group: patients will continue to receive second generation antipsychotic as usual. However, they will also receive 5 mg of memantine daily for the fir

Eligibility

Sex/Gender

All

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Patients with schizophrenia who have received a diagnosis of schizophrenia within the past three years. Schizophrenia patients must have taken a stable dose of an atypical antipsychotic at least 2 months before the study and have reached a stable condition. Patients must complete a written consent form to enter the study. There are no restrictions or prohibitions on receiving memantine

Exclusion criteria

Exclusion criteria: Having a serious medical condition (respiratory, brain disorders) Having kidney disease Having a specific medical condition that affects the patient's cognitive status (such as seizures, delirium, multiple sclerosis, brain tumor) Intellectual disability Pregnant or breastfeeding women

Design outcomes

Primary

Measure	Time frame
Total cognitive function. Timepoint: Before the intervention and 8 weeks after treatment. Method of measurement: Neuropsychiatry Unit Cognitive Assessment.	—

Secondary

Measure	Time frame
Attention score. Timepoint: Before the intervention and 8 weeks after treatment. Method of measurement: Neuropsychiatry Unit Cognitive Assessment.;Visuospatial capacity score. Timepoint: Before the intervention and 8 weeks after treatment. Method of measurement: Neuropsychiatry Unit Cognitive Assessment.;Memory score. Timepoint: Before the intervention and 8 weeks after treatment. Method of measurement: Neuropsychiatry Unit Cognitive Assessment.;Executive function score. Timepoint: Before the intervention and 8 weeks after treatment. Method of measurement: Neuropsychiatry Unit Cognitive Assessment.;Language score. Timepoint: Before the intervention and 8 weeks after treatment. Method of measurement: Neuropsychiatry Unit Cognitive Assessment.	—

Measure

Time frame

Attention score. Timepoint: Before the intervention and 8 weeks after treatment. Method of measurement: Neuropsychiatry Unit Cognitive Assessment.;Visuospatial capacity score. Timepoint: Before the intervention and 8 weeks after treatment. Method of measurement: Neuropsychiatry Unit Cognitive Assessment.;Memory score. Timepoint: Before the intervention and 8 weeks after treatment. Method of measurement: Neuropsychiatry Unit Cognitive Assessment.;Executive function score. Timepoint: Before the intervention and 8 weeks after treatment. Method of measurement: Neuropsychiatry Unit Cognitive Assessment.;Language score. Timepoint: Before the intervention and 8 weeks after treatment. Method of measurement: Neuropsychiatry Unit Cognitive Assessment.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSomayyeh Rahimi

Shiraz University of Medical Sciences

somayyehrahimi@sums.ac.ir+98 71 3226 8454

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026